Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 47 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 9783550

    Highly potent inhibitors of porcupine

    The Board of Regents of the University of Texas System · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  2. US 9775876

    Compositions and methods for CaMKII inhibitors and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 3, 2017 · Expires Sep 28, 2037

    granted
  3. US 9777024

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Oct 3, 2017 · Expires Sep 28, 2037

    granted
  4. US 9771366

    Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors

    PHOENIX MOLECULAR DESIGNS · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  5. US 9771585

    miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)

    MIRAGEN THERAPEUTICS, INC. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  6. US 9771361

    Inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  7. US 9771337

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  8. US 9765055

    Intramolecular hydrogen-bonded nitric oxide synthase inhibitors

    Northwestern University · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  9. US 9765099

    STAT6 inhibitors

    The Board of Regents of the University of Texas System · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  10. US 9765066

    Selective HDAC1 and HDAC2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  11. US 9757382

    Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

    Asana BioSciences, LLC · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  12. US 9752144

    Inhibitors of MYH7B and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  13. US 9750717

    Inhibitors of CD40-TRAF6 interaction

    Ludwig-Maximilians-Universitat Munchen · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  14. US 9750748

    Pyridazinones as DAAO enzyme inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  15. US 9745314

    MDM2 inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted
  16. US 9745255

    Meta-substituted biphenyl peripherally restricted FAAH inhibitors

    The Regents of the University of California · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted
  17. US 9738629

    Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  18. US 9738641

    Bicyclic inhibitors

    KalVista Pharmaceuticals Limited · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  19. US 9737598

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  20. US 9732095

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  21. US 9732070

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  22. US 9725448

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  23. US 9725470

    Substituted naphthyridines as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  24. US 9724350

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted